Nature Medicine最新文献_第2页

Author Correction: Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9 作者更正：Rps14单倍体缺陷导致由S100A8和S100A9介导的红细胞分化受阻

IF 58.7 1区医学

Nature Medicine Pub Date : 2024-10-23 DOI: 10.1038/s41591-024-03350-7

Rebekka K Schneider, Monica Schenone, Monica Ventura Ferreira, Rafael Kramann, Cailin E Joyce, Christina Hartigan, Fabian Beier, Tim H Brümmendorf, Ulrich Germing, Uwe Platzbecker, Guntram Büsche, Ruth Knüchel, Michelle C Chen, Christopher S Waters, Edwin Chen, Lisa P Chu, Carl D Novina, R Coleman Lindsley, Steven A Carr, Benjamin L Ebert

引用次数: 0

Economics, equity and avoidable mortality 经济学、公平和可避免的死亡率

IF 58.7 1区医学

Nature Medicine Pub Date : 2024-10-22 DOI: 10.1038/s41591-024-03303-0

Jeong-Yeon Cho, Nathorn Chaiyakunapruk

引用次数: 0

An ethics assessment tool for artificial intelligence implementation in healthcare: CARE-AI 医疗保健领域实施人工智能的伦理评估工具：CARE-AI

IF 58.7 1区医学

Nature Medicine Pub Date : 2024-10-18 DOI: 10.1038/s41591-024-03310-1

Yilin Ning, Xiaoxuan Liu, Gary S. Collins, Karel G. M. Moons, Melissa McCradden, Daniel Shu Wei Ting, Jasmine Chiat Ling Ong, Benjamin Alan Goldstein, Siegfried K. Wagner, Pearse A. Keane, Eric J. Topol, Nan Liu

引用次数: 0

Cell therapy for neurological disorders 神经系统疾病的细胞疗法

IF 58.7 1区医学

Nature Medicine Pub Date : 2024-10-15 DOI: 10.1038/s41591-024-03281-3

Soshana P. Svendsen, Clive N. Svendsen

{"title":"Cell therapy for neurological disorders","authors":"Soshana P. Svendsen, Clive N. Svendsen","doi":"10.1038/s41591-024-03281-3","DOIUrl":"10.1038/s41591-024-03281-3","url":null,"abstract":"Cell therapies for neurological disorders are entering the clinic and present unique challenges and opportunities compared with conventional medicines. They have the potential to replace damaged nervous tissue and integrate into the brain or spinal cord to produce functional effects for the lifetime of the patient, which could revolutionize the way clinicians treat debilitating neurological disorders. The major challenge has been cell sourcing, which historically relied mainly on fetal brain tissue. This has largely been overcome with the advent of pluripotent stem cell technology and the ability to make almost any cell of the nervous system at scale. Furthermore, advances in gene editing now allow the generation of genetically modified cells that could perform better and evade the immune system. With all the remarkable new approaches to treat neurological disorders, we take a critical look at the state of current clinical trials and how challenges may be overcome with the evolving technology and innovation occurring in the stem cell field. This Review summarizes the state of clinical research on cell replacement therapy for neurological conditions, and discusses the challenges facing the field, from immunosuppression and therapeutic delivery to cost issues.","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":"30 10","pages":"2756-2770"},"PeriodicalIF":58.7,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142436181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

How to make cardiology clinical trials more inclusive 如何使心脏病学临床试验更具包容性

IF 58.7 1区医学

Nature Medicine Pub Date : 2024-10-14 DOI: 10.1038/s41591-024-03273-3

Faiez Zannad, Otavio Berwanger, Stefano Corda, Martin R. Cowie, Habib Gamra, C. Michael Gibson, Alexandra Goncalves, Thomas Hucko, Kamlesh Khunti, Maciej Kostrubiec, Bettina Johanna Kraus, Cecilia Linde, Thomas F. Lüscher, Marion Mafham, Richard Mindham, Rebecca F. Ortega, Eva Prescott, Lehana Thabane, Clyde Yancy, André Ziegler, Harriette G. C. Van Spall

{"title":"How to make cardiology clinical trials more inclusive","authors":"Faiez Zannad, Otavio Berwanger, Stefano Corda, Martin R. Cowie, Habib Gamra, C. Michael Gibson, Alexandra Goncalves, Thomas Hucko, Kamlesh Khunti, Maciej Kostrubiec, Bettina Johanna Kraus, Cecilia Linde, Thomas F. Lüscher, Marion Mafham, Richard Mindham, Rebecca F. Ortega, Eva Prescott, Lehana Thabane, Clyde Yancy, André Ziegler, Harriette G. C. Van Spall","doi":"10.1038/s41591-024-03273-3","DOIUrl":"10.1038/s41591-024-03273-3","url":null,"abstract":"Cardiovascular clinical trials continue to under-represent children, older adults, females and people from ethnic minority groups relative to population disease distribution. Here we describe strategies to foster trial representativeness, with proposed actions at the levels of trial funding, design, conduct and dissemination. In particular, trial representativeness may be increased through broad recruitment strategies and site selection criteria that reflect the diversity of patients in the catchment area, as well as limiting unjustified exclusion criteria and using pragmatic designs that minimize research burden on patients (including embedded and decentralized trials). Trial communications ought to be culturally appropriate; engaging diverse people with lived experience in the co-design of some trial elements may foster this. The demographics of trialists themselves are associated with participant demographics; therefore, trial leadership must be actively diversified. Funding bodies and journals increasingly require the reporting of sociodemographic characteristics of trial participants, and regulatory bodies now provide guidance on increasing trial diversity; these steps may increase the momentum towards change. Although this Perspective focuses on the cardiovascular trial context, many of these strategies could be applied to other fields. Cardiology trials continue to under-represent certain population groups relative to disease distribution; this Perspective outlines strategies to foster representativeness and create a research enterprise that meets the needs of people living with cardiovascular disease.","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":"30 10","pages":"2745-2755"},"PeriodicalIF":58.7,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41591-024-03273-3.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142430569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Putting children’s safety at the heart of violence research 将儿童安全置于暴力研究的核心位置

IF 58.7 1区医学

Nature Medicine Pub Date : 2024-10-11 DOI: 10.1038/s41591-024-03291-1

Amiya Bhatia, Anja Zinke-Allmang, Clare Ahabwe Bangirana, Janet Nakuti, Mathew Amollo, Angel Faridah Mirembe, Progress Nangati, Alessandra Guedes, Karen Carter, Amber Peterman, Karen Devries

引用次数: 0

People with cardiac pacemakers require multidisciplinary care 心脏起搏器患者需要多学科护理

IF 58.7 1区医学

Nature Medicine Pub Date : 2024-10-09 DOI: 10.1038/s41591-024-03296-w

Kevin Vernooy, Antonius M. W. van Stipdonk, Jacqueline Joza

引用次数: 0

To conquer antimicrobial resistance in Africa, build local capacity 要战胜非洲的抗菌药耐药性，就必须建设当地的能力

IF 58.7 1区医学

Nature Medicine Pub Date : 2024-10-09 DOI: 10.1038/s41591-024-03325-8

引用次数: 0

How do plastics, including microplastics and plastic-associated chemicals, affect human health? 塑料（包括微塑料和塑料相关化学品）如何影响人类健康？

IF 58.7 1区医学

Nature Medicine Pub Date : 2024-10-08 DOI: 10.1038/s41591-024-03287-x

Bhedita J. Seewoo, Louise M. Goodes, Kevin V. Thomas, Cassandra Rauert, Ahmed Elagali, Anne-Louise Ponsonby, Christos Symeonides, Sarah A. Dunlop

引用次数: 0

Author Correction: MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial 作者更正：MDMA辅助疗法治疗中重度创伤后应激障碍：随机、安慰剂对照第3阶段试验

IF 58.7 1区医学

Nature Medicine Pub Date : 2024-10-07 DOI: 10.1038/s41591-024-03331-w

Jennifer M. Mitchell, Marcela Ot’alora G, Bessel van der Kolk, Scott Shannon, Michael Bogenschutz, Yevgeniy Gelfand, Casey Paleos, Christopher R. Nicholas, Sylvestre Quevedo, Brooke Balliett, Scott Hamilton, Michael Mithoefer, Sarah Kleiman, Kelly Parker-Guilbert, Keren Tzarfaty, Charlotte Harrison, Alberdina de Boer, Rick Doblin, Berra Yazar-Klosinski, MAPP2 Study Collaborator Group

引用次数: 0